GlobeNewsWire
27 Jul 2026, 11:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri trial failed to meet its primary endpoint of achieving a statistically significant reduction in Stage III-IV cancers. — Failure to meet a primary clinical endpoint for a flagship product directly undermines the company's core value proposition and commercial viability.
-0.80GRAIL is facing a securities fraud class action lawsuit alleging the company misled investors regarding the design and potential of the NHS-Galleri trial. — Legal proceedings for fraud create significant financial liability and reputational risk, further depressing investor confidence.
-0.40GRAIL's stock price dropped by approximately 50% following the disclosure of the trial's failure to meet its primary endpoint. — This reflects the immediate market devaluation already priced in, though it establishes the scale of the loss for shareholders.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities fraud class action lawsuit following a 50% stock drop and failure to meet primary trial endpoints.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
